Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

5.120 +0.130 (+2.62%)
Streaming Delayed Price Updated: 9:53 AM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
Via Investor Brand Network
Topics Artificial Intelligence
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial
Via Investor Brand Network
Topics Artificial Intelligence
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
Via Investor Brand Network
Topics Artificial Intelligence
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Panna Sharma, Lantern Pharma CEO, Says FDA’s Elsa AI Rollout Underscores Urgency to Modernize
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.